CRL4b Inhibition Ameliorates Experimental Autoimmune Encephalomyelitis Progression

Area of Science:

• Neuroimmunology
• Molecular Biology
• Genetics

Background:

• Multiple sclerosis (MS) and its mouse model, experimental autoimmune encephalomyelitis (EAE), are T cell-mediated autoimmune diseases of the central nervous system (CNS).
• Current therapies for MS have limitations, driving the need for novel therapeutic targets.
• Cullin-RING E3 ubiquitin ligase 4b (CRL4b) is crucial for genome stability in T cells.

Purpose of the Study:

• To investigate the role of CRL4b in T cell expansion and its involvement in driving EAE.
• To evaluate the therapeutic potential of CRL4b inhibition in EAE.

Main Methods:

• Generated mice with T cell-specific deletion of Cul4b (Cullin 4b).
• Assessed EAE clinical scores, T cell populations in the CNS, and cytokine production.
• Utilized in vitro T cell cultures and a CRL4 inhibitor (KH-4-43) in EAE mouse models.

Main Results:

• Mice lacking Cul4b in T cells exhibited reduced EAE symptoms, decreased CNS inflammation, and fewer T cells (CD4+ and CD8+).
• Cul4b-deficient T cells showed impaired expansion and differentiation into effector cells.
• In vitro CRL4 inhibition of wild-type T cells led to increased apoptosis and DNA damage.
• In vivo treatment with KH-4-43 stabilized EAE clinical scores and reduced immune cell infiltration in the CNS.

Conclusions:

• CRL4b is essential for T cell expansion and pathogenicity in EAE.
• Therapeutic inhibition of CRL4b or related pathways presents a promising strategy for treating autoimmune diseases.